- Home
- XPEV vs GMAB Comparison
XPEV vs GMAB Comparison
Compare XPEV & GMAB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- XPEV
- GMAB
- Stock Information
- Founded
- XPEV 2015
- GMAB 1999
- Country
- XPEV China
- GMAB Denmark
- Employees
- XPEV N/A
- GMAB N/A
- Industry
- XPEV Auto Manufacturing
- GMAB Biotechnology: Pharmaceutical Preparations
- Sector
- XPEV Consumer Discretionary
- GMAB Health Care
- Exchange
- XPEV Nasdaq
- GMAB Nasdaq
- Market Cap
- XPEV 12.0B
- GMAB 12.1B
- IPO Year
- XPEV 2020
- GMAB N/A
- Fundamental
- Price
- XPEV $18.43
- GMAB $22.34
- Analyst Decision
- XPEV Buy
- GMAB Buy
- Analyst Count
- XPEV 8
- GMAB 9
- Target Price
- XPEV $13.84
- GMAB $40.71
- AVG Volume (30 Days)
- XPEV 10.7M
- GMAB 1.9M
- Earning Date
- XPEV 03-18-2025
- GMAB 02-12-2025
- Dividend Yield
- XPEV N/A
- GMAB N/A
- EPS Growth
- XPEV N/A
- GMAB 83.82
- EPS
- XPEV N/A
- GMAB 16.85
- Revenue
- XPEV $5,390,497,248.00
- GMAB $2,988,286,182.00
- Revenue This Year
- XPEV $36.06
- GMAB $18.78
- Revenue Next Year
- XPEV $74.76
- GMAB $14.98
- P/E Ratio
- XPEV N/A
- GMAB $12.94
- Revenue Growth
- XPEV 66.09
- GMAB 30.67
- 52 Week Low
- XPEV $6.55
- GMAB $18.64
- 52 Week High
- XPEV $19.36
- GMAB $31.88
- Technical
- Relative Strength Index (RSI)
- XPEV 69.24
- GMAB 65.39
- Support Level
- XPEV $17.46
- GMAB $18.74
- Resistance Level
- XPEV $18.29
- GMAB $22.55
- Average True Range (ATR)
- XPEV 0.70
- GMAB 0.46
- MACD
- XPEV 0.11
- GMAB 0.39
- Stochastic Oscillator
- XPEV 79.78
- GMAB 94.64
About XPEV XPeng Inc.
Founded in 2015, XPeng is a leading Chinese smart electric vehicle company that designs, develops, manufactures, and markets EVs in China. Its products primarily target the growing base of technology-savvy middle-class consumers in the midrange to high-end segment in China's passenger vehicle market. The company sold over 141,000 EVs in 2023, accounting for about 2% of China's passenger new energy vehicle market. It is also a leader in autonomous driving technology.
About GMAB Genmab A/S ADS
Genmab AS is a Copenhagen-based biotechnology company specializing in antibody therapeutics for the treatment of cancer. Genmab's proprietary antibody technologies are DuoBody, HexaBody, DuoHexaBody, and HexElect. Johnson & Johnson partnered with Genmab to create Darzalex, which is regarded as the standard of care for multiple myeloma and is Genmab's leading product. Genmab also has Tepezza for thyroid eye disease (partnered with Horizon), Kesimpta for relapsing multiple sclerosis (partnered with Novartis), Rybrevant (partnered with Johnson & Johnson) for non-small cell lung cancer (NSCLC), Tivdak (partnered with Seagen) for cervical cancer, and Epkinly (partnered with AbbVie) for diffuse large B-cell lymphoma. Genmab has several pipeline candidates targeting other oncologic indications.